T2 Biosystems Inc (TTOO) - News Archive

T2 Biosystems Extends Partnership with Vizient Despite Financial Instability LEXINGTON, Mass. In a move that underscores its commitment to addressing critical healthcare challenges, T2 Biosystems, Inc. (NASDAQ: TTOO), a...

T2 Biosystems Surpasses Key Milestone with 250,000 Sepsis Tests Shipped Globally Amid Financial Challenges In a significant achievement for T2 Biosystems Inc, the company has successfully shipped its 250,000th novel sep...

T2 Biosystems Strengthens European Market Presence with Strategic Instrument Sale T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has announced a significant s...

The ever-evolving landscape of antimicrobial resistance (AMR) presents an increasingly formidable challenge to public health worldwide. In response to this growing crisis, two cutting-edge biotechnology companies, T2 Bi...

T2 Biosystems Receives FDA Clearance to Market T2Candida Panel for Pediatric Patients Amid Financial Challenges T2 Biosystems Inc. a prominent player in the field of innovative diagnostic solutions, has achieved a signi...

T2 Biosystems Accelerates Development of New Diagnostic Products and Implements Stock Split Strategy to Benefit ShareholdersT2 Biosystems Inc. a pioneering company specializing in innovative diagnostic tools, has recent...

In a bold move marking its commitment to addressing global health challenges, T2 Biosystems, Inc. (NASDAQ:TTOO), a prominent player in rapid detection technologies for sepsis-causing pathogens, has announced significant...

In a major step towards expanding its commercial presence, T2 Biosystems, Inc. (NASDAQ:TTOO), a pioneer in rapidly detecting sepsis-causing pathogens and antibiotic resistant genes, has announced the signing of an exclu...

T2 Biosystems, a leading company in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has recently made significant strides in ensuring its compliance with Nasdaq listing rules. This comes...

LEXINGTON, Mass., May 17, 2024 - T2 Biosystems, Inc. (NASDAQ: TTOO), a renowned company specializing in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is pleased to announce the success...

T2 Biosystems: Strategies for Growth and Economic ResilienceIn recent developments, T2 Biosystems Inc, a prominent developer of innovative diagnostic tools, has announced two significant moves with varying implications...

T2 Biosystems Inc, a renowned medical diagnostics company, has achieved significant improvements in its financial position over the past year. By reducing its total debt by approximately 80%, the company has successfull...

T2 Biosystems Shareholders Approve Conversion of $15 Million CRG Debt into EquityT2 Biosystems, Inc. (NASDAQ:TTOO) recently announced the results of a special meeting of stockholders where they voted in favor of convert...

LEXINGTON, Mass., March 28, 2024 - T2 Biosystems, a renowned leader in rapid sepsis pathogen detection and antibiotic resistance gene identification, has announced the extension of its multi-year capital equipment suppl...

In a recent announcement, T2 Biosystems, a renowned diagnostic company, has revealed its plans and progress regarding the commercial launch of their ground-breaking T2Lyme Panel in the third quarter of 2024. This signif...

In a bid to tackle the rising concern of sepsis and antibiotic resistance, T2 Biosystems, Inc. (NASDAQ:TTOO) has made significant strides in rapid disease detection. With their latest announcement of the T2Lyme Panel la...

T2 Biosystems, a leading diagnostics company, has recently published a study highlighting the clinical benefits and performance of their groundbreaking T2Resistance Panel. This study has demonstrated that the utilizatio...

T2 Biosystems Strengthens Financial Position and Enhances Shareholder Value with Strategic MovesIn recent news, T2 Biosystems, a leader in rapid detection technology for sepsis-causing pathogens and antibiotic resistanc...

T2 Biosystems Expands its Presence in Europe and Asia through Distribution PartnershipsLEXINGTON, Mass., Feb. 15, 2024 - T2 Biosystems, a renowned leader in rapid pathogen and antibiotic resistance detection for sepsis,...

In a significant move towards revolutionizing the field of diagnostics, T2 Biosystems recently announced receiving FDA 510(k) clearance for the expanded T2Bacteria Panel. This ground-breaking development in microbial de...